Now has full ownership of 2X-121, which is being developed as an anti-cancer therapeutic, as well as being tested as an anti-viral agent against COVID-19.
Dr. Ural of Ernst & Young LLP discusses market dynamics, enduring therapeutic areas, near term M&A, and how industry can use this time for transformation
As companies move their cell and gene therapies through the development process, supporting larger Phase III trials and commercial launches will be a challenge
Ryan Carpentier, Executive Director of Business Development, Cryoport09.23.19
Contract Pharma asked a roundtable of business leaders from Symbiosis, Grifols, Althea, LSNE and Baxter to discuss key trends in the parenteral dosage development and manufacturing market
The parenteral drug sector is driven by new cancer drugs and a considerable number of biologics. Veteran performers, like Baxter Biopharma, brace for growth.